2014-16年捷克共和国抗生素耐药性调查(SOAR)结果
该调查分析了2014-16年捷克共和国社区获得性呼吸道感染患者分离的肺炎链球菌和流感嗜血杆菌的药敏情况。肺炎链球菌(n=200)对阿莫西林、阿莫西林/克拉维酸、青霉素(静脉非脑膜炎)、头孢曲松、头孢呋辛和氟喹诺酮类敏感率>95%,对克拉霉素敏感率最低(37.1%的流感嗜血杆菌)。作者认为两种主要呼吸道病原体的耐药率仍低,支持当地临床医生继续限制性使用抗生素并选择窄谱药物。
要点
- 肺炎链球菌对阿莫西林、阿莫西林/克拉维酸、青霉素(静脉非脑膜炎)、头孢曲松、头孢呋辛和氟喹诺酮类敏感率>95%(CLSI折点)。
- 流感嗜血杆菌对阿莫西林/克拉维酸、头孢曲松、头孢呋辛、阿奇霉素和氟喹诺酮类敏感率≥98%(CLSI标准)。
- 流感嗜血杆菌产β-内酰胺酶率为13.7%,未发现β-内酰胺酶阴性耐氨苄西林(BLNAR)菌株(CLSI标准)。
核心结论
- 捷克共和国两种主要呼吸道病原体的抗生素耐药率仍低,支持当地临床医生继续限制性使用抗生素并选择窄谱药物进行社区获得性呼吸道感染的經驗性治疗。
研究设计与样本
- 研究分析了2014-16年从捷克共和国社区获得性呼吸道感染患者收集的肺炎链球菌和流感嗜血杆菌分离株。
- 采用CLSI肉汤微量稀释法测定MIC,并使用CLSI、EUCAST和药代动力学/药效学(PK/PD)折点评估敏感性。
主要发现
- 肺炎链球菌(n=200)对阿莫西林、阿莫西林/克拉维酸、青霉素(静脉非脑膜炎)、头孢曲松、头孢呋辛和氟喹诺酮类的敏感率>95%(CLSI折点)。
- 肺炎链球菌对头孢克洛和甲氧苄啶/磺胺甲噁唑的敏感率为94%-94.5%,对青霉素(口服)为91.5%,对大环内酯类为89.5%。
- 流感嗜血杆菌(n=197)对阿莫西林/克拉维酸、头孢曲松、头孢呋辛、阿奇霉素和氟喹诺酮类的敏感率≥98%(CLSI标准)。
- 流感嗜血杆菌对克拉霉素的敏感率为37.1%,对头孢呋辛(口服)的敏感率按CLSI标准为98.0%、按PK/PD标准为69.5%、按EUCAST标准为1.5%。
- 流感嗜血杆菌的β-内酰胺酶率为13.7%,按CLSI标准未发现BLNAR分离株。
临床怎么用
- 作者认为这些发现支持当地临床医生继续限制性使用抗生素,并为社区获得性呼吸道感染的經驗性治疗选择窄谱药物。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine the antibiotic susceptibility of isolates of Streptococcus pneumoniae and Haemophilus influenzae collected in 2014-16 from patients with community-acquired respiratory infections in the Czech Republic. METHODS: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: S. pneumoniae isolates (n = 200) showed high rates of susceptibility (>95%) to amoxicillin, amoxicillin/clavulanic acid, penicillin [intravenous (iv) non-meningitis], ceftriaxone, cefuroxime and the fluoroquinolones using CLSI breakpoints. Susceptibility to cefaclor and trimethoprim/sulfamethoxazole was 94%-94.5%, to penicillin (oral) 91.5% and to the macrolides 89.5%. Susceptibility of H. influenzae (n = 197) to amoxicillin/clavulanic acid, ceftriaxone, cefuroxime, azithromycin and the fluoroquinolones was ≥98% by CLSI criteria. Rates of susceptibility to the remaining agents were ≥75% except for clarithromycin at 37.1%. Great variability was seen across breakpoints, especially for the macrolides, cefaclor and cefuroxime (oral), 98.0% of H. influenzae showing susceptibility to the latter by CLSI criteria, 69.5% by PK/PD and 1.5% by EUCAST standards. The β-lactamase rate was 13.7% with no β-lactamase-negative-ampicillin-resistant (BLNAR) isolates by CLSI criteria. CONCLUSIONS: Antibiotic resistance among the two major respiratory pathogens remained low in the Czech Republic. These findings support local clinicians in continuing the historically restrictive use of antibiotics in the Czech Republic, with selection of narrower-spectrum agents for the empirical therapy of community-acquired respiratory tract infections. This highlights one of the great benefits of continuous surveillance of antimicrobial resistance: knowledge of current local resistance patterns reduces the need to choose broad-spectrum agents that contribute to increasing resistance worldwide.
引用
- Torumkuney D, Zemlickova H, Maruscak M, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in the Czech Republic. J Antimicrob Chemother. 2018. PMID: 29659883. doi:10.1093/jac/dky067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。